+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019

  • ID: 4778166
  • Drug Pipelines
  • June 2019
  • Region: Global
  • 57 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech Inc
  • Gossamer Bio Inc
  • KBP BioSciences Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • MORE
Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019

Summary

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation.

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 11 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 2, 1, 2 and 1 respectively. Report covers products from therapy areas Respiratory, Dermatology, Ear Nose Throat Disorders, Immunology and Gastrointestinal which include indications Asthma, Androgenic Alopecia, Chronic Obstructive Pulmonary Disease (COPD), Nasal Polyps (Nasal Polyposis), Allergic Asthma, Allergies, Chronic Urticaria Or Hives, Esophagitis, Inflammation and Rhinosinusitis.

The latest report Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
  • The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech Inc
  • Gossamer Bio Inc
  • KBP BioSciences Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • MORE
Introduction

Report Coverage

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development

Allergan Plc

Brickell Biotech Inc

Gossamer Bio Inc

Idorsia Pharmaceutical Ltd

KBP BioSciences Co Ltd

Merck & Co Inc

Novartis AG

Oxagen Ltd

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles

ACT-774312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADC-3680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-5000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fevipiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

litapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8318 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setipiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PTGDR2 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Timapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones

Featured News & Press Releases

Feb 13, 2019: Asthma pill targets airway muscles to decrease attacks

Nov 05, 2018: Novartis provides update on QAW039

Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma

Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma

Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers

Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis

Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss

Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease

Feb 18, 2015: The US FDA approved KBP-7026 to enter Phase I clinical trial

Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study

Aug 01, 2014: Eleventa has enrolled first patients in Phase III multicenter clinical trial

Jul 28, 2014: Eleventa enrolled the first patients into the multi-center center clinical study of the 3rd phase of antiasthmatic drug

Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma

Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis

May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indication, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Allergan Plc, H1 2019

Pipeline by Brickell Biotech Inc, H1 2019

Pipeline by Gossamer Bio Inc, H1 2019

Pipeline by Idorsia Pharmaceutical Ltd, H1 2019

Pipeline by KBP BioSciences Co Ltd, H1 2019

Pipeline by Merck & Co Inc, H1 2019

Pipeline by Novartis AG, H1 2019

Pipeline by Oxagen Ltd, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Dormant Products, H1 2019 (Contd..2), H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
  • Allergan Plc
  • Brickell Biotech Inc
  • Gossamer Bio Inc
  • Idorsia Pharmaceutical Ltd
  • KBP BioSciences Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Oxagen Ltd
Note: Product cover images may vary from those shown
Adroll
adroll